Focusing on eye health for World Glaucoma Week

by Mark Steedman, PhD


This week is World Glaucoma Week, aimed at raising awareness around glaucoma – a group of eye diseases that lead to damage to the optic nerve and can cause permanent vision loss. World Glaucoma Week encourages people to have regular eye checks to detect glaucoma (and other eye diseases) early and pursue treatment to preserve their vision.1

Continue reading

Posted on 16/03/2018 | 0 Comments

Robots, AI, and cognitive analysis: How technology is disrupting hospitals around the globe

By Terri Cooper, PhD, and Dr. Stephanie Allen

Disruption blog

In our Predictions 2022 report, The future awakens, we highlight as one of our six predictions that ‘the culture in health care is being transformed by digital technologies’, with smart health care delivering more cost-effective patient-centred care through digitally-enabled hospitals. This week’s blog first appeared as a US Center for Health Solutions blog, A view from the Center. It discusses in more detail how rapidly-evolving technologies and growing consumerism, along with demographic and economic changes, are already disrupting hospitals and considers how several megatrends might impact how hospitals of the future are staffed, sized, and designed.

Continue reading

Posted on 09/03/2018 | 0 Comments

As biosimilars enter the US market, will they be used, and can they reduce spending?

by Thomas Croisier and James Forsyth, Deloitte Consulting, LLP


This week’s blog is by Tomas Croisier and James Forsyth, a partner and director in our life sciences consulting practice, respectively. It was first featured in a blog post on the US Center of Health Solutions site, and explores the impact of biosimilars may have on the treatment of oncology, particularly in the US.1

Continue reading

Posted on 01/03/2018 | 0 Comments

Time to Care: Securing a future for the hospital workforce in the UK


On Monday 19th of February we launched the UK cut of our Time to care report at a jointly sponsored Cambridge Health Network event at the Deloitte offices here in London. Our UK report builds on our larger European study, launched last November, which examined the workforce challenges and actions needed to secure a sustainable clinical workforce for the future in 15 countries across Europe. Our UK report takes a deeper look at the research evidence collected for the European report, including the crowdsourced survey of hospital doctors and nurses. We supplemented the research with further interviews, data analysis, literature reviews and insights from Deloitte staff working with NHS and private sector clients across the four UK countries. Although we acknowledge the significant challenges currently facing the hospital and wider healthcare sector, we identify a huge amount of positivity and commitment from employers and staff and highlight 17 evidence based case examples of innovative approaches to tackling staff recruitment, retention and deployment.

Continue reading

Posted on 23/02/2018 | 0 Comments

Innovating life sciences in the fourth industrial revolution: Embrace, build, grow.


The term ‘revolution’ is often used to define a popular uprising that can lead to dramatic political changes. A dictator is overthrown, a new government is formed, a constitution is changed or replaced, and immeasurable impact on the country or even the world can occur. However, other types of revolutions also happen. Some of the most commonly known are industrial revolutions, which refer to breakthroughs in technology that change how industries function. We are now seeing the beginnings of a fourth industrial revolution – a fusing of technologies blurring the boundaries between the physical, digital and biological worlds.1 This blog highlights the issues that Deloitte believe will cause the most disruption for life sciences in 2018 as we embark on this fourth industrial revolution.

Continue reading

Posted on 16/02/2018 | 0 Comments

UK cancer survival rates still trailing European peers


Most people will have been impacted by cancer in some way – whether themselves, a family member, a loved one or an acquaintance. Stories about the causes of cancer and examples of exciting new breakthrough treatments feature regularly in media headlines. However, one issue more than any others attracts attention, and that’s evidence of inequalities in patient outcomes. Last week’s World Cancer Day, on 4th February, coincided with the publication of the CONCORD-3 report, comparing the outcomes for cancer patients from 73 different countries over the period 2000-2014.1 This week’s blog reflects on some of the developments in the UK given the results of this ground breaking research suggests that the UK continues to lag behind many other comparable European countries. 

Continue reading

Posted on 12/02/2018 | 0 Comments

Time to Care: A spotlight on the hospital workforce in Ireland

Time to care

In November 2017 we published our report Time to care: Securing a future for the hospital workforce in Europe. The research for the report examined how hospitals in 14 countries across Europe are responding to the challenge of clinical workforce shortages in the face of growing demands from people with more complex health care needs. It identified universal concern about workforce shortages and the lack of time for hands-on care. Last week, Deloitte Ireland published it’s Time to care report supplement, based on its analysis of our research evidence on the Irish healthcare system, particularly the findings from the Irish cohort of our crowdsourced survey.

Continue reading

Posted on 02/02/2018 | 0 Comments

Smart health care: Left hand, meet right hand


As discussed in our report The future awakens: Life Sciences and Health Care Predictions 2022, incorporating technologies into our health care systems is crucially important if we are to improve both the patient journey and the efficiency and effectiveness of our health care services. This week’s blog is by Terri Cooper, Deloitte’s Global Health Care Sector Leader and first featured as a US Centre blog in November 2017.1  Her blog examines the ways technology can improve the delivery of health care, and reviews some of the key use cases developed by 33 participants in a crowdsourced simulation exercise facilitated by the US Center for Health Solutions.

Continue reading

Posted on 25/01/2018 | 0 Comments

A new future for R&D? Applying emerging technologies to improve R&D productivity


In December, we published our eighth annual report on Measuring the return from pharmaceutical innovation. This series of reports tracks the annual return on investment (ROI) that 12 leading biopharma companies (by 2009 R&D spend) are projected to achieve from their late-stage pipelines. For the third consecutive year, we also tracked the performance of an extension cohort of four mid-to-large cap biopharma companies in order to compare their performance with our original cohort. This week’s blog briefly summarises the performance of our two cohorts and then explores some emerging technologies that we anticipate should increase the productivity and efficiency by which drugs are discovered, developed and brought to patients.

Continue reading

Posted on 19/01/2018 | 0 Comments

2018 Global health care outlook: The evolution of smart health care


This week Deloitte launched its report, 2018 Global health care outlook: The evolution of smart health care - which looks at the challenges health care will be facing in 2018 and the strategies that can be utilised to alleviate the pressures facing the sector globally. This week’s blog highlights some of the key findings from the report and their implications for the UK.

Continue reading

Posted on 12/01/2018 | 0 Comments

A new future for R&D? My take on the state of pharmaceutical innovation in 2017


This week, we published our eighth annual report on Measuring the return from pharmaceutical innovation. Our report tracks the annual return on investment that the 12 leading biopharma companies (by 2009 R&D spend) might expect to achieve from their late-stage pipelines, as well as tracking the performance of an extension cohort of four mid-to-large cap biopharma companies for the third consecutive year. This week's blog by Matthew Thaxter, an analyst at the centre, gives his take on the findings from this year’s report.

Continue reading

Posted on 14/12/2017 | 0 Comments